Investor Relations

Latest Financial Results

Latest Annual Filing

For Fiscal Year Ending Dec 31, 2021

Company Overview

NRx Pharmaceuticals is an agile and specialized CNS biopharma company, resolutely focused on meeting very high unmet medical needs for those with severe bipolar despression with suicidality and post-traumatic stress disorder (PTSD).

We are developing NRX-100/101, the first sequential drug regimen for bipolar depression in patients with acute suicidal ideation and behavior (the "NRx Antidepressant Drug Regimen"). NRx Pharmaceuticals (Nasdaq: NRXP), formerly NeuroRx, is now traded on the Nasdaq Global Select Exchange.



Incorporated Address

NRx Pharmaceuticals, Inc.
1201 Orange Street
Suite 600
Wilmington, DE 19801
T: 484-254-6134

IR Contacts

Company

NRx Pharmaceuticals, Inc.
1201 Market Street
Suite 111
Wilmington, DE 19801
T: 484-254-6134

Investor Relations

Ryan Sheffield
Chief of Staff & Military/Veteran Liaison
T: 484-254-6134 ext. 723
rsheffield@nrxpharma.com

Transfer Agent

Continental Stock Transfer & Trust